Pfizer (NYSE:PFE) Trading Up 1.9% – Here’s What Happened

Pfizer Inc. (NYSE:PFE) shares traded up 1.9% during trading on Friday . The stock traded as high as $26.76 and last traded at $26.7030. Approximately 42,345,897 shares changed hands during mid-day trading, a decline of 0% from the average daily volume of 42,439,617 shares. The stock had previously closed at $26.20.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings and guidance supported the stock. Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus and revenue of $15.03 billion versus expectations of $14.40 billion. Management also raised its 2026 revenue outlook and increased its cost-savings target to approximately $2.5 billion. Stronger demand for Eliquis and growth from newer products helped offset weaker COVID-related sales. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Pipeline and vaccine updates added support. Pfizer and BioNTech advanced a variant-adapted COVID-19 booster into a Phase 4 study and reported progress on a next-generation pediatric booster. Pfizer also completed an early Phase 1 study of PF-07328948, providing additional evidence of ongoing pipeline development beyond its mature products. Pfizer and BioNTech Advance Variant-Adapted COVID-19 Booster in New Phase 4 Study
• Positive Sentiment: Valuation and dividend appeal remain part of the bull case. Some coverage describes PFE as undervalued following the raised outlook, while Pfizer’s high dividend yield continues to attract income-focused investors. Analysts have also highlighted the company’s newer-product growth and expanding R&D pipeline. Pfizer Could Be 12% Undervalued Following Raised 2026 Revenue Guidance
• Neutral Sentiment: Insider-trading activity is drawing attention. Increased insider transactions were reported after PFE’s recent advance, but the available report does not establish whether the activity represents meaningful buying or selling. Monster insider trading alert for Pfizer stock
• Negative Sentiment: COVID and obesity-related uncertainties remain overhangs. Pfizer’s COVID pill revenue reportedly fell sharply, and investors remain concerned about patent expirations and the need for successful pipeline launches. Recent coverage also points to setbacks or uncertainty surrounding the company’s obesity program. RBC Capital Markets maintained a Hold rating, underscoring the mixed outlook. Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Bank of America cut their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Citigroup lifted their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Up 1.9%

The firm has a 50 day moving average price of $25.01 and a 200-day moving average price of $26.16. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.94. The firm has a market cap of $152.20 billion, a price-to-earnings ratio of 35.14 and a beta of 0.34.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the company posted $0.78 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s dividend payout ratio is presently 226.32%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently modified their holdings of the stock. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Keb Asset Management LLC bought a new stake in Pfizer in the second quarter valued at approximately $26,000. HFM Investment Advisors LLC raised its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Evolution Wealth Management Inc. boosted its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.